Literature DB >> 29969628

MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma.

Qiaoli Wu1, Lixia Xu1, Chen Wang1, Weijia Fan1, Hua Yan2, Qingguo Li3.   

Abstract

MiR-124-3p and EphA2 are aberrantly expressed in glioma tissue specimens. In the present study, we firstly investigated that miR-124-3p inhibits EphA2 expression mediated by binding its 3'-UTR to regulate the progression of human glioma. The U87MG and LN229 cells were transfected with miR-124-3p mimics and/or siRNA-EphA2, and then the role of miR-124-3p and EphA2 in the colony-formation, cell-cycle, migration and invasion of glioma cells in vitro were examined. Proteins involved in the epithelial-mesenchymal transition were examined using western blot. The results showed that miR-124-3p was significantly downregulated in glioma tissues, whereas a marked upregulation of EphA2 expression was found. Colony-formation and flow cytometry assays demonstrated that EphA2 downregulation or miR-124-3p mimics caused growth and cell-cycle inhibition in glioma. Transwell migration and invasion assays demonstrated that EphA2 downregulation or miR-124-3p mimics suppressed the migration and invasion of glioma cells. EphA2 downregulation or miR-124-3p mimics reduced the level of vimentin in U87MG and LN229 cells. In conclusion, miR-124-3p was found to suppress the growth, migration and invasion of glioma cells in vitro via EphA2. Furthermore, we validated miR-124-3p enforced its biological modulation via targeting EphA2 through the rescue experiment. Conclusively, our study proclaimed that miR-124-3p can counteract the malignant phenotypes of glioma cells by the inhibitory effect of the EphA2.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  EphA2; Glioma; MicroRNA-124-3p; Motility

Mesh:

Substances:

Year:  2018        PMID: 29969628     DOI: 10.1016/j.bbrc.2018.06.173

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Inhibition of EMMPRIN by microRNA-124 suppresses the growth, invasion and tumorigenicity of gliomas.

Authors:  Yanbin Song; Lei Bai; Feiping Yan; Chen Chen
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

2.  MicroRNA-505-3p inhibits development of glioma by targeting HMGB1 and regulating AKT expression.

Authors:  Zhenlin Cheng; Bin Wang; Cheng Zhang
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

3.  Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR-124-3p/CCND2 axis.

Authors:  Chen Li; Hongjiang Liu; Jipeng Yang; Jiankai Yang; Liang Yang; Yuanyu Wang; Zhongjie Yan; Yuchen Sun; Xiaofeng Sun; Baohua Jiao
Journal:  J Cell Mol Med       Date:  2019-04-11       Impact factor: 5.310

4.  MicroRNA‑124 negatively regulates chloride intracellular channel 1 to suppress the migration and invasion of liver cancer cells.

Authors:  Xupeng Yue; Yuanyuan Cui; Qi You; Yanxin Lu; Jufeng Zhang
Journal:  Oncol Rep       Date:  2019-07-25       Impact factor: 3.906

5.  Knockdown of lncRNA HOXA-AS2 Inhibits Viability, Migration and Invasion of Osteosarcoma Cells by miR-124-3p/E2F3.

Authors:  Linyi Wang; Lijuan Wang; Xinhua Zhang
Journal:  Onco Targets Ther       Date:  2019-12-11       Impact factor: 4.147

6.  Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma.

Authors:  Guowei Li; Qing Lan
Journal:  J Transl Med       Date:  2021-10-24       Impact factor: 5.531

7.  Elevated Hexose-6-Phosphate Dehydrogenase Regulated by OSMR-AS1/hsa-miR-516b-5p Axis Correlates with Poor Prognosis and Dendritic Cells Infiltration of Glioblastoma.

Authors:  Yi-Bin Zhang; Shu-Fa Zheng; Lin-Jie Ma; Peng Lin; Huang-Cheng Shang-Guan; Yuan-Xiang Lin; De-Zhi Kang; Pei-Sen Yao
Journal:  Brain Sci       Date:  2022-07-30

Review 8.  MicroRNA-124: An emerging therapeutic target in cancer.

Authors:  Xinqi Jia; Xu Wang; Xiaorong Guo; Jingjing Ji; Ge Lou; Junjie Zhao; Wenjia Zhou; Mian Guo; Maomao Zhang; Chao Li; Sheng Tai; Shan Yu
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.